Logo image of MNKD

MANNKIND CORP (MNKD) Stock Price, Quote, News and Overview

NASDAQ:MNKD - Nasdaq - US56400P7069 - Common Stock - Currency: USD

5.76  +0.1 (+1.77%)

After market: 5.8001 +0.04 (+0.7%)

MNKD Quote, Performance and Key Statistics

MANNKIND CORP

NASDAQ:MNKD (2/21/2025, 8:00:01 PM)

After market: 5.8001 +0.04 (+0.7%)

5.76

+0.1 (+1.77%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High7.63
52 Week Low3.47
Market Cap1.59B
Shares275.78M
Float270.76M
Yearly DividendN/A
Dividend YieldN/A
PE115.2
Fwd PE23.05
Earnings (Next)02-26 2025-02-26/amc
IPO07-28 2004-07-28


MNKD short term performance overview.The bars show the price performance of MNKD in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 -5 -10 -15

MNKD long term performance overview.The bars show the price performance of MNKD in the last 1, 2 and 3 years. 1 year 2 years 3 years 20 40 60 80 100

The current stock price of MNKD is 5.76 USD. In the past month the price decreased by -3.19%. In the past year, price increased by 62.25%.

MANNKIND CORP / MNKD Daily stock chart

MNKD Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.97 357.10B
AMGN AMGEN INC 15.29 162.72B
GILD GILEAD SCIENCES INC 23.85 137.00B
VRTX VERTEX PHARMACEUTICALS INC 1669.79 124.40B
REGN REGENERON PHARMACEUTICALS 15.34 76.56B
ARGX ARGENX SE - ADR N/A 39.16B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.32B
BNTX BIONTECH SE-ADR N/A 28.77B
ONC BEIGENE LTD-ADR N/A 27.25B
NTRA NATERA INC N/A 21.43B
BIIB BIOGEN INC 8.54 20.49B
SMMT SUMMIT THERAPEUTICS INC N/A 16.31B

About MNKD

Company Profile

MNKD logo image MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. The company is headquartered in Danbury, Connecticut and currently employs 414 full-time employees. The company went IPO on 2004-07-28. The company is focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. Its technologies include Technosphere dry-powder formulations and Dreamboat inhalation devices, which offers delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. Its products include Afrezza (insulin human) Inhalation Powder and the V-Go wearable insulin delivery device. The Afrezza (insulin human) Inhalation Powder is an inhaled insulin indicated to enhance glycemic control in adults with diabetes. The V-Go wearable insulin delivery device provides subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease pipeline includes Tyvaso DPI (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Company Info

MANNKIND CORP

1 Casper Street

Danbury CONNECTICUT 91362 US

CEO: Michael E. Castagna

Employees: 414

Company Website: https://mannkindcorp.com/

Investor Relations: https://investors.mannkindcorp.com

Phone: 18186615000

MANNKIND CORP / MNKD FAQ

What is the stock price of MANNKIND CORP today?

The current stock price of MNKD is 5.76 USD. The price increased by 1.77% in the last trading session.


What is the ticker symbol for MANNKIND CORP stock?

The exchange symbol of MANNKIND CORP is MNKD and it is listed on the Nasdaq exchange.


On which exchange is MNKD stock listed?

MNKD stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for MANNKIND CORP stock?

11 analysts have analysed MNKD and the average price target is 10.2 USD. This implies a price increase of 77.08% is expected in the next year compared to the current price of 5.76. Check the MANNKIND CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is MANNKIND CORP worth?

MANNKIND CORP (MNKD) has a market capitalization of 1.59B USD. This makes MNKD a Small Cap stock.


How many employees does MANNKIND CORP have?

MANNKIND CORP (MNKD) currently has 414 employees.


What are the support and resistance levels for MANNKIND CORP (MNKD) stock?

MANNKIND CORP (MNKD) has a support level at 5.44 and a resistance level at 5.77. Check the full technical report for a detailed analysis of MNKD support and resistance levels.


Is MANNKIND CORP (MNKD) expected to grow?

The Revenue of MANNKIND CORP (MNKD) is expected to grow by 45.04% in the next year. Check the estimates tab for more information on the MNKD EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy MANNKIND CORP (MNKD) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does MANNKIND CORP (MNKD) stock pay dividends?

MNKD does not pay a dividend.


When does MANNKIND CORP (MNKD) report earnings?

MANNKIND CORP (MNKD) will report earnings on 2025-02-26, after the market close.


What is the Price/Earnings (PE) ratio of MANNKIND CORP (MNKD)?

The PE ratio for MANNKIND CORP (MNKD) is 115.2. This is based on the reported non-GAAP earnings per share of 0.05 and the current share price of 5.76 USD. Check the full fundamental report for a full analysis of the valuation metrics for MNKD.


What is the Short Interest ratio of MANNKIND CORP (MNKD) stock?

The outstanding short interest for MANNKIND CORP (MNKD) is 10.08% of its float. Check the ownership tab for more information on the MNKD short interest.


MNKD Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to MNKD. When comparing the yearly performance of all stocks, MNKD is one of the better performing stocks in the market, outperforming 87.46% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

MNKD Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to MNKD. MNKD has an average financial health and profitability rating.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

MNKD Financial Highlights

Over the last trailing twelve months MNKD reported a non-GAAP Earnings per Share(EPS) of 0.05. The EPS increased by 141.67% compared to the year before.


Industry RankSector Rank
PM (TTM) 8.07%
ROA 4.65%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%100%
Sales Q2Q%36.73%
EPS 1Y (TTM)141.67%
Revenue 1Y (TTM)51.3%

MNKD Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 85% to MNKD. The Buy consensus is the average rating of analysts ratings from 11 analysts.

For the next year, analysts expect an EPS growth of 320.32% and a revenue growth 45.04% for MNKD


Ownership
Inst Owners61.62%
Ins Owners1.42%
Short Float %10.08%
Short Ratio11.49
Analysts
Analysts85.45
Price Target10.2 (77.08%)
EPS Next Y320.32%
Revenue Next Year45.04%